Statements (34)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvedBy |
1952
|
| gptkbp:ATCCode |
S01EC01
|
| gptkbp:brand |
gptkb:acetazolamide
|
| gptkbp:CASNumber |
59-66-5
|
| gptkbp:chemicalFormula |
C4H6N4O3S2
|
| gptkbp:contraindication |
severe liver disease
sulfa allergy adrenal gland failure |
| gptkbp:discoveredBy |
gptkb:Bernard_B._Brodie
|
| gptkbp:eliminationHalfLife |
10-15 hours
|
| gptkbp:excretion |
renal
|
| https://www.w3.org/2000/01/rdf-schema#label |
Diamox
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Teva_Pharmaceuticals
|
| gptkbp:mechanismOfAction |
carbonic anhydrase inhibitor
|
| gptkbp:metabolism |
minimal
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:sideEffect |
nausea
vomiting diarrhea fatigue loss of appetite tingling |
| gptkbp:usedFor |
gptkb:pseudotumor_cerebri
congestive heart failure epilepsy altitude sickness glaucoma |
| gptkbp:bfsParent |
gptkb:Acetazolamide
gptkb:acetazolamide |
| gptkbp:bfsLayer |
7
|